

ChemoTech



When life science matters

ChemoTech announces outcome of the directed issue

NOT FOR DISCLOSURE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER STATE OR JURISDICTION WHERE DISCLOSURE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES UNDER APPLICABLE LAW. PLEASE REFER TO "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Scandinavian ChemoTech AB (publ) ("ChemoTech" or the "Company") today announces the outcome of the directed issue of class A shares which was proposed by the shareholder Martin Jerndal on 31 March 2026 and resolved by the annual general meeting on 5 May 2026 (the "Directed Issue"). Through the Directed Issue, the Company issued 761,191 new class A shares, totalling approximately SEK 2.55 million, and the Company's CEO, members of the board and current investors have subscribed for the new class A shares. All class A shares have been allotted, and the issue proceeds have been paid by set-off of the respective subscriber's claim against the Company.

The Directed Issue

ChemoTech today announces the outcome of the Directed Issue which was proposed by the shareholder Martin Jerndal on 31 March 2026 and resolved by the annual general meeting on 5 May 2026. Through the Directed Issue, the Company issued 761,191 new class A shares, totalling approximately SEK 2.55 million. The subscribers in the Directed Issue are APAC Equity Management PTE Ltd (Mohan Frick, CEO) with approximately SEK 750 thousand, Britt-Marie Frick and Anders Frick with approximately SEK 750 thousand, BEngström Förvaltning AB (Bengt Engström, board member) with approximately SEK 800 thousand and Reomics AB (Rolf Ehrnström, board member) with approximately SEK 250 thousand. All new class A shares have been subscribed for and allotted. The issue proceeds are paid by set-off of the respective subscriber's claim against the Company. The subscription price in the Directed Issue is SEK 3.35 per class A share, which corresponds to a discount of approximately 10.00 per cent against the volume-weighted average price of the Company's class B share on Nasdaq First North Growth Market during the period 16-27 March 2026.

The purpose of the Directed Issue is to reduce the Company's debt burden by set-off against outstanding loans, thereby reducing the cost of capital. The reason why the Directed Issue was directed to existing shareholders was that these shareholders have expressed and demonstrated a long-term interest in the Company, which creates security and stability for both the Company and its shareholders, as well as significant strategic and long-term value. Further, it was the proposer's assessment that without the support of existing shareholders, it would not have been possible to carry out a successful capital raising. The proposing shareholder further noted that it is also in the interests of the Company and its shareholders that members of the board of directors and the Company's management have an interest in the Company's long-term development.

Share capital, number of shares and dilution

The Directed Issue means that the share capital will increase by SEK 380,595.50, from SEK 12,726,989.00 to SEK 13,107,584.50, and that the number of shares will increase by 761,191 shares, from 25,453,978 shares to 26,215,169 shares, where 2,412,857 are class A shares and 23,802,312 are class B shares. This corresponds to a dilution of approximately 2.90 per cent of the total number of shares and approximately 7.36 per cent of the total number of votes in the Company.

Advisors

Moll Wendén Advokatbyrå AB acts as legal advisor to ChemoTech and Mangold Fondkommission AB acts as issuing agent in connection with the Directed Issue.

Important information

The publication, release or distribution of this press release may be subject to legal restrictions in certain jurisdictions, and persons in those jurisdictions where this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable rules in their respective jurisdiction. This press release does not constitute an offer to sell or a solicitation of an offer to acquire or subscribe for securities issued by the Company in any jurisdiction where such an offer or solicitation would be unlawful. In a Member State of the European Economic Area (“**EEA**”), securities referred to in this announcement may only be offered in accordance with the applicable exemptions under Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”).

This press release does not constitute a prospectus within the meaning of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction.

This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without the application of an exemption from registration, under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold in the United States unless they are registered, are covered by an exemption from, or are part of a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be disclosed, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such disclosure, publication or distribution of this information would be contrary to applicable regulations, or where such action is subject to legal restrictions or would require further registration or other measures beyond those required under Swedish law. Any action contrary to this instruction may constitute a breach of applicable securities legislation.

In the United Kingdom, this document and any other material relating to the securities referred to herein are distributed and directed solely to, and any investment or investment activity relating to this document is available only to and may be undertaken only by, “**qualified investors**” (as defined in section 86(7) of the UK Financial Services and Markets Act 2000) who are (i) persons who have professional experience in investment business and who fall within the definition of “**investment professionals**” in Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“the Order”); or (ii) “**high net worth entities**” as referred to in Article 49(2)(a)-(d) of the Order (all such persons are collectively referred to as “**relevant persons**”). An investment or investment activity to which this notice relates is available in the UK only to relevant persons and will be undertaken only with relevant persons. Persons who are not relevant persons should not take any action based on this document, nor act or rely on it.

This press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in new shares. An investment decision to acquire or subscribe for new shares in the Company may only be made on the basis of publicly available information, which has not been verified by ChemoTech’s financial advisers. The Company’s financial advisers are acting on behalf of the Company in connection with the transaction and not on behalf of any other party. The Company’s financial advisers are not liable to any other party for providing the protection afforded to their clients or for providing advice in connection with the transaction or in relation to any other matter mentioned herein.

Forward-looking statements

This press release contains forward-looking statements relating to the Company’s intentions, assessments or expectations regarding the Company’s future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities, as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the use of terms such as “believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “assume”, “should”, “could” and, in each case, the negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no guarantee that they will materialise or that they are correct. As these assumptions are based on estimates and are subject to risks and uncertainties, the actual results or outcomes may, for a variety of reasons, differ materially from those indicated in the forward-looking statements. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressly or implicitly set out in this press release through the forward-looking statements.

The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct, and readers of the press release should not unduly rely on the forward-looking statements contained herein. The information, views and forward-looking statements expressly or implicitly contained herein are provided only as of the date of this press release and are subject to change. Neither the Company nor any other party undertakes to review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise regarding the content of this press release, unless required by law or the rules of Nasdaq First North Growth Market.

Information for distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended (“**MiFID II**”); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the “**MiFID II Product Governance Requirements**”), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any “manufacturer” (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in ChemoTech have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the “**Target Market Assessment**”). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in ChemoTech may decline and investors could lose all or part of their investment; the shares in ChemoTech offer no guaranteed income and no capital protection; and an investment in the shares in ChemoTech is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Directed Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in ChemoTech.

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in ChemoTech and determining appropriate distribution channels.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye Nordic Growth AB is the company's Certified Adviser. Read more at: www.chemotech.se.